Current advance of nanotechnology in diagnosis and treatment for malignant tumors

B Wang, S Hu, Y Teng, J Chen, H Wang, Y Xu… - … and Targeted Therapy, 2024 - nature.com
Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary
field that is garnering a lot of interest and investigation. Nanomedicine shows great potential …

Chondrosarcoma: a clinical review

A Gazendam, S Popovic, N Parasu… - Journal of Clinical …, 2023 - mdpi.com
Chondrosarcomas are a diverse group of malignant cartilaginous matrix-producing
neoplasms. Conventional chondrosarcomas are a continuum of disease based on the …

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

MM Gounder, NP Agaram, SE Trabucco… - Nature …, 2022 - nature.com
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

[HTML][HTML] Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

C Wang, S Dai, X Zhao, Y Zhang, L Gong, K Fu… - Biomedicine & …, 2023 - Elsevier
Celastrol is a pentacyclic triterpenoid extracted from the traditional Chinese medicine
Tripterygium wilfordii Hook F., which has multiple pharmacological activities. In particular …

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

F Duffaud, O Mir, P Boudou-Rouquette… - The Lancet …, 2019 - thelancet.com
Background Regorafenib has proven activity in patients with pretreated gastrointestinal
stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to …

Personalized chordoma organoids for drug discovery studies

A Al Shihabi, A Davarifar, HTL Nguyen, N Tavanaie… - Science …, 2022 - science.org
Chordomas are rare tumors of notochordal origin, most commonly arising in the sacrum or
skull base. Chordomas are considered insensitive to conventional chemotherapy, and their …

An overview of resistance to chemotherapy in osteosarcoma and future perspectives

DY Garcia-Ortega, SA Cabrera-Nieto… - Cancer drug …, 2022 - pmc.ncbi.nlm.nih.gov
Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of
multimodal treatment with surgery and chemotherapy, the clinical results remain …

A 3D-printed orthopedic implant with dual-effect synergy based on MoS2 and hydroxyapatite nanoparticles for tumor therapy and bone regeneration

W Dai, Y Zheng, B Li, F Yang, W Chen, Y Li… - Colloids and Surfaces B …, 2023 - Elsevier
Treatments for malignant bone tumors are urgently needed to be developed due to the
dilemma of precise resection of tumor tissue and subsequent bone defects. Although …

[HTML][HTML] Nanomaterial-assisted theranosis of bone diseases

K Zheng, J Bai, H Yang, Y Xu, G Pan, H Wang… - Bioactive Materials, 2023 - Elsevier
Bone-related diseases refer to a group of skeletal disorders that are characterized by bone
and cartilage destruction. Conventional approaches can regulate bone homeostasis to a …

[HTML][HTML] Ewing sarcoma

S Durer, DP Gasalberti, H Shaikh - StatPearls [Internet], 2024 - ncbi.nlm.nih.gov
Objectives: Identify early manifestations of Ewing sarcoma, distinguishing them from
common bone pathologies in adolescents. Differentiate between localized and metastatic …